Breast Cancer Research and Treatment

, Volume 128, Issue 3, pp 783–794

Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial

Authors

  • Sirwan Hadad
    • Dundee Cancer CenterUniversity of Dundee, Ninewells Hospital and Medical School
  • Takayuki Iwamoto
    • Department of Breast Medical OncologyM.D. Anderson Cancer Center
  • Lee Jordan
    • Dundee Cancer CenterUniversity of Dundee, Ninewells Hospital and Medical School
  • Colin Purdie
    • Dundee Cancer CenterUniversity of Dundee, Ninewells Hospital and Medical School
  • Susan Bray
    • Dundee Cancer CenterUniversity of Dundee, Ninewells Hospital and Medical School
  • Lee Baker
    • Dundee Cancer CenterUniversity of Dundee, Ninewells Hospital and Medical School
  • Gera Jellema
    • Almac Diagnostics
  • Steve Deharo
    • Almac Diagnostics
  • D. Grahame Hardie
    • College of Life SciencesUniversity of Dundee
  • Lajos Pusztai
    • Department of Breast Medical OncologyM.D. Anderson Cancer Center
  • Stacy Moulder-Thompson
    • Department of Breast Medical OncologyM.D. Anderson Cancer Center
  • John A. Dewar
    • Dundee Cancer CenterUniversity of Dundee, Ninewells Hospital and Medical School
    • Dundee Cancer CenterUniversity of Dundee, Ninewells Hospital and Medical School
    • Department of Surgical OncologyM.D. Anderson Cancer Center
Clinical trial

DOI: 10.1007/s10549-011-1612-1

Cite this article as:
Hadad, S., Iwamoto, T., Jordan, L. et al. Breast Cancer Res Treat (2011) 128: 783. doi:10.1007/s10549-011-1612-1

Abstract

Metformin may reduce the incidence of breast cancer and enhance response to neoadjuvant chemotherapy in diabetic women. This trial examined the effects of metformin on Ki67 and gene expression in primary breast cancer. Non-diabetic women with operable invasive breast cancer received pre-operative metformin. A pilot cohort of eight patients had core biopsy of the cancer at presentation, a week later (without treatment; internal control), then following metformin 500-mg o.d. for 1 week increased to 1-g b.d. for a further week continued to surgery. A further 47 patients had core biopsy at diagnosis were randomized to metformin (the same dose regimen) or no drug, and 2 weeks later had core biopsy at surgery. Ki67 immunohistochemistry, transcriptome analysis on formalin-fixed paraffin-embedded cores and serum insulin determination were performed blinded to treatment. Seven patients (7/32, 21.9%) receiving metformin withdrew because of gastrointestinal upset. The mean percentage of cells staining for Ki67 fell significantly following metformin treatment in both the pilot cohort (P = 0.041, paired t-test) and in the metformin arm (P = 0.027, Wilcoxon rank test) but was unchanged in the internal control or metformin control arms. Messenger RNA expression was significantly downregulated by metformin for PDE3B (phosphodiesterase 3B, cGMP-inhibited; a critical regulator of cAMP levels that affect activation of AMP-activated protein kinase, AMPK), confirmed by immunohistochemistry, SSR3, TP53 and CCDC14. By ingenuity pathway analysis, the tumour necrosis factor receptor 1 (TNFR1) signaling pathway was most affected by metformin: TGFB and MEKK were upregulated and cdc42 downregulated; mTOR and AMPK pathways were also affected. Gene set analysis additionally revealed that p53, BRCA1 and cell cycle pathways also had reduced expression following metformin. Mean serum insulin remained stable in patients receiving metformin but rose in control patients. This trial presents biomarker evidence for anti-proliferative effects of metformin in women with breast cancer and provides support for therapeutic trials of metformin.

Keywords

Breast cancer Metformin ki67 Transcriptome analyses Clinical trial

Supplementary material

10549_2011_1612_MOESM1_ESM.ppt (1.3 mb)
Supplementary Figure A. Gene networks revealed by differentially expressed genes using t-test. These figures were generated using Ingenuity Pathway Analysis tool loading the genes that were identified as significantly over- or underexpressed between baseline and follow-up biopsies by t-test. (P ≤ 0.01). The top 10 networks are shown, red = genes overexpressed post-metformin and green = underexpressed post-metformin. White = pathway member not present in the gene list of interest. (PPT 1298 kb)
10549_2011_1612_MOESM2_ESM.doc (374 kb)
Supplementary material 2 (DOC 374 kb)
10549_2011_1612_MOESM3_ESM.doc (166 kb)
Supplementary material 3 (DOC 165 kb)
10549_2011_1612_MOESM4_ESM.ppt (4.1 mb)
Supplementary Figure B Gene networks revealed by GSA for metformin effect These 20 figures were generated using Ingenuity Pathway Analysis loading genes that were significant from the Gene Set Analysis. The genes from Supplementary Table 2 were used and genes were included if parametric P value ≤ 0.1 (red = genes overexpressed post-metformin, green = underexpressed post-metformin, grey = no significant change (P ≤ 0.1), white = pathway member not present in the gene list of interest). (PPT 3419 kb)

Copyright information

© Springer Science+Business Media, LLC. 2011